Physician profile
Omar Shams
NPI 1093906133
$12,080.24
in general payments reported to CMS, 2019-2025
45 companies · $1,646 in 2025
The $1,646 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,917 · 2020: $753 · 2021: $953 · 2022: $951 · 2023: $1,864 · 2024: $1,996 · 2025: $1,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,506 · Consulting Fee: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,506.14 |
| Consulting Fee | $2,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,378.87 | 2019-2025 | Watchman Access System, Watchman, Watchman Flx |
| Medtronic Vascular, INC. | $925.11 | 2019-2020 | |
| Medtronic, INC. | $782.27 | 2021-2023 | Cobalt Dr Mri Surescan, Micra |
| Biosense Webster, INC. | $699.87 | 2019-2023 | Carto 3, Thermocool Smarttouch |
| Medical Device Business Services, INC. | $654.66 | 2019 | |
| Abbott Laboratories | $536.99 | 2019-2024 | Aveir |
| Novartis Pharmaceuticals Corporation | $373.01 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $358.69 | 2019-2025 | Lifevest |
| Baxter Healthcare | $318.25 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| E.R. Squibb & Sons, L.L.C. | $308.33 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $259.99 | 2019-2025 | |
| Philips North America LLC | $246.85 | 2019-2025 | Ecc Solutions |
| Atricure, INC. | $242.98 | 2019-2023 | |
| Scpharmaceuticals INC. | $219.06 | 2024-2025 | |
| Novo Nordisk INC | $213.70 | 2024-2025 | Wegovy |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Shams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.